Why This Matters

1. Diabetic Foot Ulcers Are Common, Recurrent, and Deadly
Up to one-third of patients with diabetes will develop a foot ulcer in their lifetime, and recurrence rates approach 40% within one year of healing. DFUs precede 85% of diabetes-related amputations, and 5-year mortality after major amputation can reach 40% to 70%—making comprehensive foot assessment a limb- and life-saving priority.
2. Neuropathy and PAD Are High-Impact, Often Underassessed Risk Factors
Approximately 50% of individuals with diabetes develop peripheral neuropathy, and up to half of patients with DFUs have coexisting peripheral arterial disease. Without systematic sensory and vascular evaluation, clinicians may miss critical risk multipliers that directly influence healing potential, amputation risk, and survival.
3. Standardized Assessment and Risk Classification Improve Outcomes and Accountability
Structured frameworks such as WIfI and ADA/IWGDF risk categories support earlier intervention, better interdisciplinary communication, and defensible documentation. In an era of value-based care and heightened scrutiny of avoidable amputations, comprehensive diabetic foot assessment is both a clinical necessity and a quality imperative.

The Growing Burden of Diabetic Foot Complications

Diabetes mellitus affects more than 37 million people in the United States, with an additional 96 million adults living with prediabetes.¹ Globally, an estimated 537 million adults are living with diabetes, and this number is projected to rise to 643 million by 2030.² As prevalence increases, so too does the incidence of diabetes-related lower extremity complications.

Diabetic foot ulcers (DFUs) are among the most common and serious complications of diabetes. Lifetime risk estimates suggest that 19% to 34% of individuals with diabetes will develop a DFU.³ Annual incidence ranges from 2% to 5%, and recurrence rates approach 40% within one year after healing and 65% within five years.³ These figures reflect a chronic, relapsing condition rather than an isolated event.

DFUs precede approximately 85% of diabetes-related lower extremity amputations.⁴ In the United States, diabetes remains the leading cause of nontraumatic lower limb amputation.1 Patients with DFUs experience a 5-year mortality rate comparable to or exceeding many cancers, with estimates ranging from 30% to 50% depending on severity and comorbidities.^3,5
Given these statistics, systematic and comprehensive foot assessment is not simply a procedural step—it is a public health imperative.

Neuropathy: The Silent Driver of Ulcer Risk

Peripheral neuropathy is a central contributor to diabetic foot pathology. Approximately 50% of individuals with diabetes develop diabetic peripheral neuropathy (DPN) during their lifetime.⁶ DPN results in loss of protective sensation (LOPS), leaving patients unable to perceive pressure, shear, or trauma.

The American Diabetes Association (ADA) recommends at least annual assessment for neuropathy using validated tools such as monofilament testing combined with other modalities (eg, vibration, pinprick, ankle reflexes).⁷ Despite this guidance, studies consistently show gaps in routine screening in primary and specialty care settings.⁸

Neuropathy is not merely a diagnostic label—it is a measurable risk multiplier. Individuals with LOPS are significantly more likely to develop foot ulcers and experience recurrence after healing.³ The absence of pain perception allows repetitive mechanical stress to progress unchecked, particularly when compounded by foot deformity or ill-fitting footwear.

From a systems perspective, failing to consistently assess and document neuropathy status represents a missed opportunity for early risk stratification. As value-based care models increasingly tie reimbursement to complication rates and quality metrics, incomplete foot assessment has downstream implications for both patient safety and institutional performance.
 

Peripheral Arterial Disease: A Major Determinant of Healing and Amputation

Peripheral arterial disease (PAD) coexists in up to 50% of patients with DFUs.⁹ Diabetes accelerates atherosclerosis and is associated with distal, multilevel arterial involvement, complicating both diagnosis and management.

PAD significantly increases the risk of nonhealing wounds and major amputation.⁹ The Society for Vascular Surgery and other international bodies emphasize objective vascular assessment in patients with suspected ischemia, yet pedal pulse documentation alone is often insufficient to detect clinically significant disease.^9,10

Patients with diabetes and PAD face dramatically worse outcomes. Compared with those without ischemia, individuals with combined neuropathy and PAD have higher rates of infection, hospitalization, and amputation.⁹ Moreover, diabetes-related amputations carry substantial mortality risk, with 5-year mortality after major amputation reported at 40% to 70%.⁵

In this context, comprehensive vascular pulse evaluation and risk classification are not academic exercises—they are determinants of limb salvage and survival. Understanding how to systematically assess perfusion and stratify risk is directly tied to measurable patient outcomes.

Risk Stratification Systems: Why Classification Matters

Risk stratification tools such as the Wound, Ischemia, and foot Infection (WIfI) classification system were developed to standardize assessment and predict amputation risk and need for revascularization.¹⁰ The WIfI score correlates strongly with 1-year amputation risk and has been validated across multiple populations.¹⁰

Similarly, structured diabetic foot risk categories recommended by the ADA and International Working Group on the Diabetic Foot (IWGDF) guide surveillance frequency and preventive strategies.^7,11 

Why does this matter? Because inconsistent or incomplete classification contributes to variability in care, delayed referrals, and preventable complications. Standardized assessment frameworks improve communication across disciplines, support documentation, and align care with evidence-based risk thresholds.

As health care systems face increasing scrutiny around avoidable amputations, structured classification is becoming a quality and compliance issue—not simply a clinical preference.

Gait, Biomechanics, and Footwear: Overlooked Drivers of Recurrence

Biomechanical abnormalities—including limited joint mobility, Charcot neuroarthropathy, hammertoes, and prominent metatarsal heads—contribute to focal pressure elevation and ulcer formation.¹¹ Plantar pressures in patients with neuropathy can exceed tissue tolerance thresholds, particularly in the absence of protective sensation.

Footwear plays a measurable role in ulcer prevention. Studies demonstrate that therapeutic footwear and custom orthoses reduce recurrence rates in high-risk patients when properly prescribed and used.¹¹ However, adherence is variable, and improper footwear remains a common contributing factor in ulcer development.

Recurrent DFUs are not rare events. As noted, up to 40% of patients experience recurrence within one year of healing.³ Each recurrence increases cumulative risk of infection, hospitalization, and amputation.

Comprehensive foot assessment that includes footwear evaluation and gait analysis provides objective insight into mechanical risk factors. From a population health perspective, failing to address biomechanical contributors perpetuates a cycle of ulcer-heal-recur that drives cost and morbidity.
 

The Economic and Health System Impact

The economic burden of diabetic foot disease is substantial. In the United States, the annual cost of diabetes-related foot complications is estimated to exceed $9 billion in direct medical costs, independent of overall diabetes expenditures.¹² Hospitalizations for DFUs and amputations contribute significantly to this figure.

Patients with DFUs have higher rates of emergency department visits, inpatient admissions, and readmissions compared with patients with diabetes without foot complications.¹² Moreover, amputation is associated with long-term disability, prosthetic needs, and loss of productivity.

From a payer and policy standpoint, preventable amputations are increasingly viewed as quality failures. Geographic variation in amputation rates across the United States suggests disparities in access to preventive and vascular care.¹³ Structured assessment and early risk identification are foundational components of closing these gaps.

For wound care professionals, comprehensive foot evaluation intersects with quality metrics, value-based purchasing, and institutional benchmarking. As regulatory scrutiny increases, documentation of neuropathy status, vascular findings, risk classification, and ulcer etiology becomes a critical part of defensible, high-quality care.

Why This Topic Demands Focus Now

The epidemiology of diabetic foot disease underscores a clear reality: rising diabetes prevalence, high ulcer recurrence, substantial amputation risk, and significant mortality converge to create an urgent need for standardized, comprehensive assessment.

Despite established guidelines, gaps persist in routine neuropathy screening, vascular assessment, and risk stratification.^7,8 These gaps translate into missed opportunities for early intervention and risk modification.

For clinicians committed to limb preservation, quality improvement, and evidence-based practice, understanding the “why” behind systematic assessment is as important as mastering the “how.” In an era of increasing clinical complexity and accountability, foundational skills in diabetic foot evaluation remain one of the most powerful tools to influence morbidity, mortality, and health system performance—from the ground up.

References
1.    Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2022. US Department of Health and Human Services; 2022.
2.    International Diabetes Federation. IDF Diabetes Atlas. 10th ed. International Diabetes Federation; 2021.
3.    Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367-2375. doi:10.1056/NEJMra1615439
4.    Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13(5):513-521. doi:10.2337/diacare.13.5.513
5.    Hoffstad O, Mitra N, Walsh J, et al. Diabetes, lower-extremity amputation, and death. Diabetes Care. 2015;38(10):1852-1857. doi:10.2337/dc15-0536
6.    Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi:10.2337/dc16-2042
7.    American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(suppl 1):S203-S215.
8.    Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc. 2011;101(2):93-115.
9.    Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with a foot ulcer and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(S1):e3276. doi:10.1002/dmrr.3276
10.    Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on Wound, Ischemia, and foot Infection (WIfI). J Vasc Surg. 2014;59(1):220-234.e2. doi:10.1016/j.jvs.2013.08.003
11.    Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF guidelines on the prevention and management of diabetic foot disease. Diabetes Metab Res Rev. 2020;36(S1):e3269. doi:10.1002/dmrr.3269
12.    Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014;37(3):651-658. doi:10.2337/dc13-2176
13.    Goodney PP, Holman K, Henke PK, et al. Regional intensity of vascular care and lower extremity amputation rates. J Vasc Surg. 2013;57(6):1471-1480.e3. doi:10.1016/j.jvs.2012.12.037